February 14, 2018
MicroRNA could help treat cancer and asthma
WEST LAFAYETTE, Ind. — A microRNA that regulates inflammation shows promise as a treatment for inflammatory diseases such as asthma and cancer, according to research published in Cell Reports.
The microRNA, known as miR-223, is highly expressed in blood cells that cause inflammation (neutrophils). When they’re working correctly, those blood cells help protect the human body against infections, but sometimes they damage host tissue instead of microbes, causing chronic inflammation and disease.
To uncover the link between miR-223 and inflammation, a Purdue University research team created a zebrafish totally deficient of miR-223. Then they cut off a small chunk of its fin.
“The inflammation was really robust,” said Qing Deng, a professor of biological sciences at Purdue and corresponding author of the paper. “Neutrophils accumulated at the wound and they just kept coming. This is consistent with the literature, but we wanted to understand why.”
Extensive gene expression analysis led them to pathway NF-kB, a protein complex found in nearly all animal cell types that regulates inflammation and cell proliferation. Heightened activation of this pathway is the cause of increased inflammation, although it’s limited to the deeper, or basal, layer of the epithelium. This means any therapeutics would need to reach the basal layer to work.
The same pathway plays an important role in human bronchial epithelial cells, which are critical in the development of asthma, according to the study. MiR-223 suppresses the pathway, which means supplementing it to epithelial cells could help control inflammatory disease.
“We don’t have human trials yet, but we think it’s promising,” Deng said. “Instead of using steroids to drive away the immune cells, maybe this microRNA could be given.”
Deng is also a researcher in the Institute of Inflammation, Immunology and Infectious Disease in Purdue’s Discovery Park.
Writer: Kayla Zacharias, 765-494-9318, email@example.com
Source: Qing Deng, 765-494-0423, firstname.lastname@example.org
MicroRNA-223 Suppresses the Canonical NF-kB Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation
Wenqing Zhou, Arpita S. Pal, Alan Yi-Hui Hsu, Theodore Gurol, Xiaoguang Zhu, Sara E. Wirbisky-Hershberger, Jennifer L. Freeman, Andrea L. Kasinski, and Qing Deng
MicroRNA-223 is known as a myeloid-enriched anti-inflammatory microRNA that is dysregulated in numerous inflammatory conditions. Here, we report that neutrophilic inflammation (wound response) is augmented in miR-223-deficient zebrafish, due pri- marily to elevated activation of the canonical nuclear factor kB (NF-kB) pathway. NF-kB over-activation is restricted to the basal layer of the surface epithelium, although miR-223 is detected throughout the epithe- lium and in phagocytes. Not only phagocytes but also epithelial cells are involved in miR-223-medi- ated regulation of neutrophils’ wound response and NF-kB activation. Cul1a/b, Traf6, and Tab1 are iden- tified as direct targets of miR-223, and their levels rise in injured epithelium lacking miR-223. In addi- tion, miR-223 is expressed in cultured human bron- chial epithelial cells, where it also downregulates NF-kB signaling. Together, this direct connection between miR-223 and the canonical NF-kB pathway provides a mechanistic understanding of the multi- faceted role of miR-223 and highlights the relevance of epithelial cells in dampening neutrophil activation.